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Role of dietary phosphate restriction in chronic kidney disease
Abstract

Aim: Patients with progressive chronic kidney disease (CKD) develop positive phosphate balance that is
associated with increased cardiovascular risk and mortality. Modification of dietary phosphate is a commonly
used strategy to improve outcomes but is complicated by the need for adequate dietary protein. Surprisingly,
the evidence for patient-level benefits from phosphate restriction is tenuous, and the justification for using any
phosphate binder for pre-dialysis patients is questionable.
Methods: The evidence for dietary phosphate modification was reviewed, along with the possible role of a
smart phone application (app) that provides information on phosphate, sodium, potassium and nutrients in
over 50 000 Australian foods. A pilot study of healthy participants assigned to dietetic advice and standard
diet sheets, or dietetic advice, diet sheets and use of the smart phone app was performed.
Results: Following baseline studies, 25 participants commenced the sodium and phosphate restricted diet.
After 2 weeks, both groups showed non-significant trends to reduction in urinary phosphate and sodium. App
users referred to information on the app more frequently than the control group participants referred to
written instructions, found referring to the app more convenient, felt they learned more new information,
were more motivated to maintain the diet and were more likely to recommend their information source to
family or friends (all P < 0.05).
Conclusions: Maintaining phosphate balance remains an important goal of CKD management, although diets
incorporating very low phosphate and protein contents may worsen patient outcomes. For selected patients, a
smart phone app may improve dietary acceptance and compliance.
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Abstract
Background and objectives
Patients with progressive chronic kidney disease (CKD) develop positive phosphate balance that is
associated with increased cardiovascular risk and mortality. Modification of dietary phosphate is a
commonly used strategy to improve outcomes but is complicated by the need for adequate dietary
protein. Surprisingly, the evidence for patient-level benefits from phosphate restriction is tenuous,
and the justification for using any phosphate binder for pre-dialysis patients is questionable.
Design, setting, participants, and measurements
We review the evidence for dietary phosphate modification and the possible role of a smart phone
application (app.) that provides information on phosphate, sodium, potassium and nutrients in over
50,000 Australian foods. We performed a pilot study of healthy participants assigned to dietetic
advice and standard diet sheets, or dietetic advice, diet sheets and use of the smart phone app.
Results
Following baseline studies, 25 participants commenced the sodium and phosphate restricted diet.
After two weeks, both groups showed non-significant trends to reduction in urinary phosphate and
sodium. App. users referred to information on the app. more frequently than the control group
participants referred to written instructions, found referring to the app. more convenient, felt they
learned more new information, were more motivated to maintain the diet and were more likely to
recommend their information source to family or friends (all p<0.05),
Conclusions
Maintaining phosphate balance remains an important goal of CKD management, although diets
incorporating very low phosphate and protein contents may worsen patient outcomes. For selected
patients, a smart phone app. may improve dietary acceptance and compliance.

Key words: phosphate, protein, dietary restriction, smart phone application, phosphate binders,
cardiovascular risk

Introduction.
Phosphate is a natural component of foods rich in protein and mixed diets usually contain 12-14 mg
per gram of protein 1. The US Institute of Medicine has recommended a dietary intake for
maintaining phosphate balance and normal serum phosphate levels of 700 mg/day for healthy
adults and up to 1250 mg/day for older children and pregnant women 2, and in Australia and New
Zealand, the recommended daily intake for adults is 1000 mg/day 3. Most studies suggest that
protein intakes of 0.6 g/kg per day are adequate, with at least 50% as high biological value protein;
containing essential amino acids in a proportion similar to that required by the body, and with a
caloric intake sufficient to maintain body weight. However, higher protein intakes of 0.75 g/kg per
day have been recommended for active young men and women and for elderly people who use
protein less efficiently and have a lower lean mass 4.These recommendations also apply to patients
with chronic kidney disease (CKD).

Bioavailable phosphate.
Phosphorus is organically bound and stored as phytate in grains, cereals and seeds. Humans and
other non-ruminant animals lack the digestive enzyme phytase that is produced by bacteria in the
gut of ruminants, and consequently humans are unable to digest phytate. This results in less than
40% of phosphate from plant sources being bioavailable and the remainder being excreted. By
comparison, phosphate derived from animal products such as meat, fish and milk is more readily
absorbed 5, and the absorption of phosphate food additives approaches 100%. These additives are
frequently used as food processing aids, as colour and flavour enhancers, to alter food texture and
to increase shelf life. Sugary carbonated beverages have added phosphoric acid to sharpen flavour
and to slow the growth of moulds and bacteria.

The challenges of calculating dietary phosphate.
Depending on the dietary source, around 60% of phosphate undergoes gastrointestinal absorption

and 95% of the absorbed phosphate is renally excreted unless renal function is severely
compromised. Intestinal phosphate absorption is responsive to levels of circulating 1,25dihydroxyvitamin D and prescribed calcitriol or other vitamin D receptor agonists (VDRAs). These
drugs can increase active phosphate absorption to around 80% by increasing intestinal type II
sodium-dependent phosphate co-transporter 2b (Npt2b) activity. With this in mind, the current
Kidney Disease Improving Global Outcomes (KDIGO) CKD-mineral and bone disorder (MBD)
guidelines no longer recommend the use of calcitriol/VDRAs for patients with CKD stages 3 to 5 and
moderate hyperparathyroidism, instead suggesting that these agents be reserved for severe and
progressive hyperparathyroidism6.

The varying bioavailability of phosphate between food sources and the effect of prescribed drugs on
phosphate absorption can lead to the dietetic assessment of phosphate intake being inaccurate. In a
study by Oenning et al. that compared dietary phosphate content using standard food tables and
chemical analyses 7, food tables underestimated the phosphate content of diets by approximately
350 mg/day. This inaccuracy was further emphasised in a recent study, which reported that
traditional methods of calculating intake from food databases overestimated the true phosphate
content of a vegetarian diet by 33%, although a fresh meat and milk product-based diet did match
database predictions 5. For patients with CKD, any reduction of dietary phosphate must be balanced
against the maintenance of adequate dietary protein, energy and normal potassium values, which
often leads to complex instructions and reduces dietary adherence.

Evidence for restricting phosphate
Restriction of dietary protein, and with it dietary phosphate, slows the progression of renal disease
in experimental animal models 8,9. In humans, elevated phosphate levels are associated with the
development and progression of CKD-MBD 10, but the benefits of intervention to restrict dietary
protein and phosphate remain unclear. Patients with renal impairment and elevated serum

phosphate values are at greater risk of coronary artery calcification, cardiovascular disease (CVD),
progression to end stage renal disease (ESRD), and early mortality 11-13. However, the Kidney Early
Evaluation Program (KEEP) study illustrated that while phosphate levels are associated with these
outcomes, they are not necessarily causative and may not be true surrogates 14. The KEEP
nationwide study screened high-risk individuals in the USA with estimated glomerular filtration rate
(eGFR) <60 ml/min per 1.73m2, and analysed risk according to quartiles of serum phosphate.
Individuals in the highest serum phosphate quartile had an unadjusted 6.72-fold higher risk of
progression to ESRD over a median follow up of 2 years than those with phosphate values of ≤3.3
mg/dl (the reference value). However, this hazard ratio was no longer significant when adjusted for
demographic data, other cardiovascular risk factors and severity of CKD. The value of pharmaceutical
interventions to reduce serum phosphate is even more controversial. When phosphate binder
effects were studied in moderate CKD 15, the risk of developing vascular calcification was greater for
patients allocated to any type of phosphate binder (lanthanum, sevelamer and calcium-based) than
to placebo.

Another potential benefit of phosphate restriction and/or phosphate binder use is to ameliorate the
dramatic rises in FGF23 that occur as CKD progresses. Although early elevations of FGF23 are
adaptive to maintain phosphate homeostasis, the extreme values found in patients with CKD are
associated with increased cardiac fibrosis, hypertrophy and arrhythmogenic potential 16,17, and with
increased progression to dialysis and increased mortality in patients with CKD stages 2-4 18.
Consequently, recent studies of protein and phosphate restriction, and of interventions using
phosphate binding agents, have focussed on FGF23 modulation as a surrogate for the amelioration
of CVD.

Evidence for patient-level benefits of protein and phosphate restriction in CKD.
Despite the cost in time and human resources invested in counselling patients on protein and

phosphate restriction, the evidence for dietary intervention is remarkably poor, and even in clinical
trials, up to 50% of patients fail to achieve dietary compliance. Table 1 summarises important
studies, most of which are randomised, controlled trials, of usual versus reduced dietary
phosphate/protein. The table also includes some studies that assessed differing phosphate sources
5,19

.

The Modification of Diet in Renal Disease (MDRD) study 20, was a major initiative to assess decline in
kidney function in relation to three levels of protein and phosphate intake (normal, low and very
low), and two levels of blood pressure management. In the primary analysis, there were no
statistically significant differences in progression between low and usual protein diets, or between
low and very low protein diets. The authors concluded that the effect of these dietary prescriptions
to patients with mild to moderate renal insufficiency remained uncertain. Further analysis suggested
that lower protein diets might slow progression in patients with the most rapid decline in GFR 21 and
each decrease in protein intake of 0.2 g/kg/day was associated with a slower mean GFR decline 22. As
a result, the authors suggested a prescribed dietary protein intake of 0.8 g/kg/day for patients with
GFR < 25 mL/min/1.73 m2.

Pedrini et al 23 performed a systematic review of studies to December 1994 that assessed usual
versus low protein dietary restriction in patients with moderate CKD (eGFR <55 ml/min/1.73m2).
That meta-analysis indicated significantly less progression of renal impairment in both non diabetic
and type 1 diabetic patients allocated to low protein diets. In five studies of non diabetic renal
impairment, the relative risk (RR) for renal failure or death was 0.67 (95% Cl, 0.50 to 0.89), and in the
five studies of patients with type-1 diabetes mellitus a low-protein diet significantly slowed increases
in urinary albumin and the decline in GFR or creatinine clearance [RR, 0.56 (Cl, 0.40 to 0.77)].
Moe et al5 investigated differences in phosphate absorption between grain-based and meat-based
diets that contained equivalent protein and phosphate, and observed higher levels of serum

phosphate and FGF23 and lower PTH levels after one week of the meat-based diet. Most recently, a
long term follow up of patients enrolled in the MDRD study 24 reported that pre-randomisation
urinary phosphate levels were not associated with long-term outcomes of ESRD or mortality,
although in a fully adjusted model a three-day dietary recall for phosphate did show a modest
association to all-cause mortality. The authors suggested that until further studies confirmed or
refuted their findings, caution should be used in advising reductions in dietary phosphate and
protein intake in patients with CKD. The chance of such a study is remote.

Improving the management of phosphate control; ‘What you eat today walks and talks
tomorrow’.
In 2013, Dr Tonelli writing in Kidney International25, suggested that a smart phone ‘food switch’
application (app.) could be developed for patients with CKD to help them control their phosphate
levels. After scanning the bar code of a product, the app. would provide information on the
phosphate content (inclusive of additives) of the selected and comparable products, so that
consumers could make a more informed choice. Of course, this relies on the availability of an
extensive, locally germane food database. With this in mind, we approached the developers of the
most downloaded, free of charge Australian dietary app. to create a version containing information
applicable to patients with CKD. The app. contained information on over 50,000 Australian foods
obtained from Australian food databases and food product labels. Patients using the app. could elect
to share data collected by the app. with their dietitian or other health professionals, to enable realtime online monitoring of their progress. When released for download, the new renal version (Easy
Diet Diary Renal™) included dietary phosphate, sodium, calcium and potassium, in addition to
protein, kilojoules and carbohydrate.

Efficacy and acceptance of a renal app. for dietetic monitoring; a pilot study.
To compare the utility of the app. to standard dietetic monitoring, we undertook a pilot study with

approval of the Human Research Ethics Committee of Western Sydney Local Health District and
adherence to the Declaration of Helsinki (ACTRN12617000558325).
Methods: After providing volunteers with study information and receiving their informed consent,
25 participants with a normal urinalysis, blood pressure and without a history of kidney disease or
use of medications likely to influence urinary sodium or phosphate values were randomly allocated
to an intervention or a control group. Next, all participants maintained a food diary for 3 days to
assess baseline dietary sodium and phosphate intakes, followed by a 24 hour urine sample for
volume, creatinine, sodium and phosphate. Participants were then requested to moderately reduce
their sodium and phosphate intake for two weeks, to daily targets often used for people with
established renal failure (ERF) of <100 mmol sodium and < 1000 mg phosphate. To achieve this, all
participants were provided with a dietary leaflet used in normal clinical care that provided advice on
strategies to achieve the reduction. Based on the dietary records, participants were given feedback
on their dietary intakes of sodium and phosphate, and provided with individualised advice on
reducing that intake to within the target range in a telephone interview of no more than 1 hour with
a trained dietician. No additional strategies were used in the control group. However, the
intervention group were given approximately 30 minutes instruction by a non-dietician on use of the
dietary app. to monitor sodium and phosphate targets.
The primary outcome was to assess within group change in 24 hour urinary phosphate and sodium
values between collections at baseline and two weeks after commencement of the diet. The
estimated sample size for this was 10 participants per arm. Calculation of between group differences
(estimated sample size 123 subjects per arm) was outside the scope of this pilot study. The
secondary outcome was to compare ease of dietary compliance between the groups using a
questionnaire completed by all participants at the conclusion of the dietary intervention. The
questionnaire included 11 questions on acceptability and usability of the food diary, five on
compliance, five free text questions and for app. users, 14 questions on ease of use.
Paired t-tests or Wilcoxon signed rank tests were used to test for differences between baseline and

end of the intervention. Independent t-tests or Wilcoxon rank sum tests were used to test for
differences between groups. Analyses were conducted by intention to treat and significance was
determined by p-values <0.05. Questionnaire responses were recorded by participants using a 5point Likert scale. Statistical analyses were undertaken using SPSS version 21 (SPSS Inc., Chicago,
Illinois, USA).
Results: Participant demographics and clinical details, dietary intakes calculated from the three day
food diaries and baseline 24 hour urinary values for sodium, phosphate and creatinine did not differ
significantly between groups (Table 2). Baseline sodium and phosphate intakes from the three day
dietary assessments were close to the 50th percentile of age adjusted population norms . However,
24 hour urinary values of sodium and phosphate, measured as a single batch after conclusion of the
study, were close to the targeted range even before any dietary intervention (Table 2). Comparison
of pre and post intervention urinary values indicated trends to reduction in mean sodium and
phosphate values that did not reach statistical significance within or between groups (Table 2) or
when values for the control and app. group were combined to assess change over the period of
dietary intervention. Comparing questionnaire responses, app. users referred to information on the
app. more frequently than the control group participants referred to written instructions, app. users
found referring to the app. more convenient, felt they learned more new information, were more
motivated to maintain the diet and were more likely to recommend their information source to
family or friends (all p<0.05), with trends to confidence in improving eating habits (p=0.06), ease of
use (p=0.07) and fewer non-compliant days (p=0.08) (Table 2) . In the free text section, six control
participants felt they lacked access to sufficient information, while no app. users indicated that they
lacked information.
Discussion: The pilot study suggested that participants using the app., which gave them immediate
access to the sodium, phosphate, potassium and nutrient content of their foods, had a better
experience of the restricted diet. Their greater motivation and self assessed increase in knowledge
of food sources was encouraging. These results can be contrasted with a study of 279 patients in 14

long-term dialysis facilities with persistently elevated phosphate levels26. Patients were allocated to
usual care or intervention that included specific instruction, handouts of preferred foods and foods
to avoid and additional telephone reinforcement. Serum phosphate levels decreased at three
months in the intervention group and food knowledge scores improved in both. However, there was
no significant difference in food knowledge between control and interventional groups as noted in
our study. Nevertheless, it is important to emphasise that before use of the app. can be endorsed
in research or with groups such as patients with CKD, further studies would be required to
determine whether the app. assists these patients to achieve their nutrient targets.
The renal app. is now available in Australasia, with approximately 450 downloads in the first six
months since its release. A screen shot of a sample breakfast is included (Figure 1). Further
modifications will differentiate foods high in organic and inorganic phosphate and provide the ‘food
switch’ capacity suggested by Dr. Tonelli in 2013.

Conclusion.
In ESRD, when phosphate homeostasis is no longer attainable through endogenous responses, a low
phosphate, high protein intake has been associated with reduced mortality, but extremely low
dietary phosphate combined with a low protein intake may produce worse outcomes. This equipoise
is not achieved by many patients. Based on the available evidence, encouragement to eat grain and
vegetable-based meals with lower inorganic phosphate, reduced phosphate additives and high-value
protein is unlikely to have adverse effects and may have benefits for most people with CKD. Reduced
reliance on calcitriol or other VDRAs to suppress PTH, and an acceptance of moderately increased
PTH levels in the later stages of CKD, will also lead to reduced intestinal phosphate absorption and
may improve phosphate balance. Although based on weak clinical evidence, it appears preferable to
target treatment towards overt hyperphosphatemia in CKD stages 3-5, rather than targeting values
of serum phosphate in the normal range. As well as being more attainable, this would reduce
adverse effects of phosphate binder therapy, including hypercalcaemia associated with calcium-

based binders. Public advocacy for the disclosure on packaged food labels of all phosphate additives,
which are the source of highly absorbed phosphate, would be a real benefit to consumers. In
addition, a renal dietary app. may encourage some users to understand and improve their food
choices and dietary compliance.
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Legend to tables 1 and 2 and to figure 1.

Table 1. Studies comparing diets containing usual versus reduced phosphate and protein. Abbreviations; CKD: chronic kidney disease, DM: diabetes
mellitus, P: phosphate, BP: blood pressure, tHcy: total homocysteine, Na: sodium, PTH: parathyroid hormone, BMI: body mass index, FGF23: fibroblast
growth factor 23, 25OHD: 25-hydroxyvitamin D, 1,25(OH)2D: 1,25-dihydroxyvitamin D, Ca: calcium, ESRD: end-stage kidney disease, CV: cardiovascular, HR:
hazard ratio, SD: standard deviation, CI: confidence interval.

Table 2. Participant demographics, dietary intakes calculated from three-day food records, pre and post study values for 24 hour urine biochemistry and
selected questionnaire responses. * p<0.05 for between group differences.
For the general population aged 19 to 30 years, the 50th percentile for usual daily sodium intake, excluding discretionally added salt, is 2247 mg for females
and 2965 mg for males and for phosphorus is 1228 mg for females and 1695 mg for males
(http://www.abs.gov.au/ausstats/abs@.nsf/Lookup/by%20Subject/4364.0.55.008~2011-12~Main%20Features~Essential%20minerals~400; accessed
September 2017). Based on the three day food diary prior to dietary intervention, 33 % of participants had sodium intakes within the target range, while
33% of control group participants had phosphate intakes within the target range. However, based on urinary sodium and phosphate values, 33% and 54% of
participants had baseline sodium values within the target range and 92% and100% had baseline phosphate values within the target range before dietary
intervention. Baseline and end of study urinary values were determined after study completion.

Figure 1. Screenshot of a sample breakfast using the app.
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Table 1.
Author and year
Hypothesis

Number available for
analysis

Study
duration

GFR / eGFR
2
ml/min/1.73m

Active intervention

Primary outcome

Secondary outcomes

Pedrini et al , 1996
(Meta analysis January
1966-December 1994;
included MDRD)

1413 non diabetic
patients (5 studies)

18-36 months

<55

Low protein: 0.4-0.6
g/kg/day vs. usual
protein

Progression of renal
disease 27% lower
in patients on low
protein diet

Benefit of low protein
diet not related to BP
lowering

Protein and P restriction
may prevent or delay
worsening of CKD
20
Klahr et al , 1994
(MDRD 1989-93)

108 patients with type 1
DM (5 studies)

9-33 months

Study A: 574

3 years

Study A: 25-55

Study B: 252

Mean 2.2
years

Study B: 13-24

574

3 years

Study A: 25-55

23

Rate of decline in kidney
function will be modified
by protein, P restriction
and BP control

21

Levey et al , 1996
(MDRD)
Rate of decline in kidney
function will be modified
by protein and P
restriction and BP
control

Low protein 0.50
g/kg/ day - 0.85
g/kg/day
Study A: usualprotein (1.3 g/kg
day) vs. low-protein
(0.58 g/kg/day}, P 510 mg/kg/day
Study B: Low-protein
0.58 g/kg/day, P: 510 mg/kg/day
vs. very low-protein
0.28 g/kg/day + keto
acids-amino acids
0.28 g/kg/day and
P 4-9 mg/kg/day
Three levels of
protein and P intake
and two levels of BP
management
Low-protein: 0.58
g/kg per day
Usual protein: 1.3
g/kg day

Study A: Projected
decline in GFR at 3
years did not differ
between diet groups

Study B: Trend (p =
0.07) toward slower
mean decline in GFR
with very lowprotein diet.
No significant effect
on time to renal
failure / death.
Effect of low-protein
diet inconclusive
due to nonlinear
GFR decline and
limited duration of
follow-up

Faster GFR decline on
low-protein diet in 1st 4
months, then slower
decline
No difference between
dietary groups over 3
years
Possible beneficial effect
of low- protein diet to
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22

Levey , 1996
(MDRD 1989-93)

252

Mean 2.2
years

Study B: 13-24

Prescribed diets for
Study B as above
Reanalysis using
achieved protein
intake calculated
from average of
monthly urea
nitrogen excretion
levels:
Low 0.73 g/kg/day
Very low 0.66
g/kg/day

The achieved lower
protein intake
retarded CKD
progression

678

1 year

13-24
25-55

Dietary protein
low vs. usual
Dietary protein low
vs. very low + amino
acids and ketoacids

No association of
protein intake to
tHcy values.

53

48 weeks

<30

Very low 0.3
g/kg/day vegetable
protein + ketoanalogues vs.
conventional low
mixed protein diet
0.6 g/kg/day

Significantly higher
serum bicarbonate
and lower serum P
in the very low
group

392

6-18 months

18±7
CKD stages 4-5

Usual and low
protein diets: 0.80
vs. 0.55 g/kg/day +

Significant betweengroup difference in
protein intake

Rate of decline in kidney
function will be modified
by protein restriction
and BP control

27

Menon , 2005
(MDRD 1989-93)
High protein intake will
be associated with
higher tHcy
19
Mircescu , 2007
Low protein intake will
improve nitrogen waste
products retention and
calcium, P and acid-base
disturbances

28

Cianciaruso , 2008
(Patients screened 19992003)

slow GFR decline in
patients with the most
rapidly declining GFR, and
to reduce urine protein
excretion
Risk of developing end
stage renal disease or
death within 3 years of
follow-up: 51% for 0.8
g/kg/day vs.30% for 0.6
g/kg/day (a 40%
reduction)
No relationship of
protein intake to change
in urine protein excretion
Keto acid-amino acid
supplements did not
influence progression
Vitamin supplementation
reduces tHcy levels in
some patients

No death in either group
No significant change in
eGFR for very low group
Fewer patients in the very
low group progressed to
dialysis; 4% vs. 27%
Limitations; small
numbers and relatively
short duration
Compliance: 27% for
0.55g and 53% for 0.8g
No significant differences
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Low protein will modify
serum urea nitrogen
concentration

5

Moe , 2011

8 (crossover)

1 week then
2 -4 week
washout then
crossover 1
week

25-40

16 (2 by 2 factorial)

2 weeks

15-60

32 (crossover)

2 weeks

21-54

Vegetarian or meat
protein sources affect
levels of serum P and
FGF23
18

Isakova , 2011
Dietary P restriction, the
P binder lanthanum or
both will reduce levels of
FGF23

29

Di Iorio , 2012
(Study 2008-2010)
Low protein and P will
reduce levels of FGF23

multivitamin and
mineral tablet daily +
calcium and iron
supplements.
Calcium, sevelamer
and bicarbonate
were used to achieve
K/DOQI targets

No significant
difference in blood
urea for intention to
treat
Increased urea with
higher protein in per
protocol analysis

Grain/soy
(vegetarian) or
meat/dairy (meat);
equivalent content of
protein and P 800
mg/day
No preservative
750 or 1500 mg
dietary P daily and
lanthanum 1g or
placebo with meals.
750 mg P added to
meals 3 times daily

After 1 week meat
vs. vegetable diet,
higher P, FGF23, and
trend to urinary P
and lower PTH

Very-low-protein (0.3
g/kg per day; 350420 mg/day P) vs.
conventional low
protein (0.6 g/kg per
day; 600-700 mg/day
P) + ketoanalogues

FGF23 fell
significantly by
33.5% in the very
low protein/P group

Neither group had
lower FGF23

in serum P/PTH/
bicarbonate or
progression of renal
failure in intention to
treat or per protocol
analyses
Lower urinary P and Na
and less P binder use in
low protein group
No change in BMI or body
weight over time,
including patients strictly
adhering to 0.55 g diet
Correlation of change in
plasma P and FGF23. No
relationship to 25OHD,
1,25(OH)2D or PTH

Lower urinary P with
lower P diet and rise in
FGF23 with higher P and
placebo
No significant changes in
serum P levels between
or within the diet or
binder groups
Limitation: short duration
Lower serum and urine P
and increased urinary P
reabsorption.
Limitation: short duration
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30

Sigrist , 2013
Altered dietary protein
influences FGF23 levels

31

Isakova , 2013
Reduced dietary P plus
lanthanum carbonate
will reduce FGF23 from
baseline

32

Goto , 2014

24

A relationship exists of
pre-randomisation
dietary P, evaluated by

FGF23 levels
respond to dietary
change in CKD
patients and
controls

In patients with CKD and
controls, higher dietary P
is associated with lower
serum 1,25(OH)2D and
higher serum P values
Limitation: short duration

P-restricted diet +
lanthanum reduced
FGF23
P-restricted diet
had borderline
effect

No between group
differences in serum P,
Ca, PTH, 1,25(OH)2D,
urinary P
Urinary P might not be
useful for monitoring
adherence or titrating
interventions aimed at
reducing FGF23
No differences in cardiac
echo parameters
PTH rose in patients on
ad libitum diet
With lower protein diet;
PTH and P levels fell in
advanced CKD
1,25(OH)2D levels
increased in early CKD
Urine P decreased in both
groups
Limitation: short duration
A direct association of 3
day dietary P recall and
all-cause mortality (HR
per SD higher 1.19 [95%
CI 1.03, 1.37], p=0.02) in
the fully adjusted model

3 weeks

15-60 (CKD group)

39: 4 groups of 8-10
patients at study
completion

12 weeks

15-60

15 (Early CKD)
20 (Advanced CKD)

<1 week

>60
<30

Regular protein; 1.11.4 g/kg/day and 1520 mg/kg/day P vs.
low protein; 0.6-0.8
g/kg/day and 10-15
mg/kg/day P

FGF23 was lower in
both groups on low
protein diet
FGF23 correlated to
urinary P excretion
only in patients with
advanced CKD

795

Mean follow
up 16 years
(0.25-22)

33±12
CKD stages 3-5

Comparison of
baseline urinary P
quartiles and
outcomes; 589
progressed to ESRD,
191 died of CV and

No statistically
significant
associations of 24hr
urinary P and
ESRD, CV, non-CV
and all cause

A standard low-protein
diet reduces FGF23 in
CKD

Selamet , 2016
(MDRD 1989-93)

and amino acids
High P: 2000 mg/day,
low P: 750 mg/day,
low P + 500 mg
aluminium hydroxide
three times daily
Low protein:76 ± 3
g/day, high protein:
82 ± 5 g/day
Ad libitum diet or
900 mg P diet ± three
times daily
lanthanum 1000 mg
or placebo

18 patients with CKD
and 12 healthy controls
(crossover)

. 32
24 hour urine P, to risks
of ESRD and mortality

228 of non-CV causes

mortality in
minimally or fully
adjusted models.

Limitation: baseline
urinary P may not reflect
long term values

. 33
Table 2.
Baseline

Baseline demographic and clinical details
Age median (IQR)
Male sex (n)
Weight (kg) median (IQR)
BMI kg/m2, mean SD
Systolic BP mean SD
Diastolic BP mean SD
Daily intakes calculated from 3 day dietary analyses (mean±SD)
Baseline vales are prior to dietary interventions
Dietary sodium
(1 mmol sodium=23 mg)
Participants (%) with dietary sodium estimation <100
mmol/day (2300 mg/day)
Dietary phosphate
(1 mmol phosphorus=31 mg)
Participants (%) with dietary phosphate estimation <1000
mg/day (32.3 mmol/day)
Protein g/day
Energy kJ/day
24 hour urine biochemistry (mean±SD)
Baseline values are prior to dietary intervention
Urinary sodium
Participants (%) with urinary sodium <100 mmol/day
(2300 mg/day)
Urinary phosphate
Participants (%) with urinary phosphate <1000 mg/day
(32.3 mmol/day)
Urinary calcium

2 weeks

Intervention
group
n=13

Control
Group
n=12

Intervention
group
n=13

Control
Group
n=12

26 (25.5-29.5)
4
64.4 (55.2-72.5)
22.56 (2.52)
111 (12)
74 (9)

26 (24.5-28.75)
5
59.5 (54.8-66.1)
23.58 (3.06)
111 (11)
69 (10)

-

-

119 (41) mmol
2734 (941) mg
33

116 (32) mmol
2665 (732) mg
33

-

-

50 (14) mmol
1554 (430) mg
0

42 (13) mmol
1305 (412) mg
33

-

-

100 (26)
9306 (2092)

88 (30)
8714 (2343)

-

-

134 (62) mmol
3082 (1426) mg
54%

126 (37) mmol
2898 (851) mg
33%

114 (62) mmol
2622 (1426) mg
75%

123 (38) mmol
2829 (874) mg
33%

27 (11) mmol
837 (326) mg
92

24 (5) mmol
744 (155) mg
100

25 (12) mmol

20 (6)mmol

83

100

4.2 (1.7) mmol

3.4 (1.5) mmol

3.4 (2.5) mmol

3.4 (1.4) mmol
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Urinary creatinine
Post study evaluation questionnaire responses
Number of days of non-compliance to the diet over the
past 2 weeks (Mean±SD)
Proportion (%) who agreed the supplementary
information/app. increased their motivation to adhere to
the diet
Number of times referring to supplementary diet
information/app. [Median (IQR]
Proportion (%) who agreed the supplementary
information/app. increased their knowledge
Proportion (%) who agreed the supplementary
information/app. increased their confidence about
following the diet

168 (68) mg
13.1 (6.6) mmol

136 (45) mg
11.1 (3.0)

136 (100) mg

136 (56) mg

-

-

2.6 (1.7)

4.9 (4.1)

-

-

50*

25

-

-

3.5 (2-3)*

2 (1.3-3)

-

-

92*

54

-

-

50*

25
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Figure 1.

